Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33
Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
Beam Therapeutics to seek approval of SCD cell therapy after trial success
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30
Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a - Slideshow
Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79
Why Beam Therapeutics Stock Is Up 15.6% And What's Next
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?
Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28
BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.